Clinical trials: 5-FU
Advanced Colorectal Cancer
Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial
The ONTOP study is a prospective, single-arm, open-label phase II clinical trial. A total of 32 patients with advanced MSS/pMMR colorectal cancer who have failed first-line treatment will receive second-line standard treatment…
- Trial name
- ONTOP (NCT07106034)
- Testing
- Ongericimab + Toripalimab + Bevacizumab + FOLFOX, Ongericimab + Toripalimab + Bevacizumab + FOLFIRI
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Shanghai Pudong Hospital
Rectal Cancer, Metastatic
Short Course Radiotherapy, Unresectable Rectal Cancer, Liver Metastasis
The purpose of this study is the increase of resection rate of primary cancer in rectal after short course radiotherapy without interrupt chemotherapy schedule during the period of chemotherapy.
- Trial name
- NCT03022734
- Testing
- chemotherapy, radiotherapy
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
This phase Ib/II trial studies the side effects and best dose of bispecific antibody armed activated T-cells when given together with aldesleukin and sargramostim and to see how well they work in treating patients with pancreatic…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT02620865
- Testing
- Aldesleukin, Antibody Therapy, Fluorouracil
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Metastatic Colorectal Cancer
CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC
The objective is to compare the efficacy and safety of CAPOXIRI+BEV therapy versus FOLFOXIRI+BEV therapy as first-line therapy in patients with metastatic colorectal cancer (mCRC).
- Trial name
- QUATTRO-II (NCT04097444)
- Testing
- Bevacizumab, 5-fluorouracil, Leucovorin calcium
- Where
- Japan
- Volunteers
- 112 people
- Sponsor
- Chugai Pharmaceutical
Irresectable Squamous Cell or Adenocarcinoma of the Oesophagus
Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus
For esophageal cancer that can not be removed by surgery, the choice of treatment is a combination of chemotherapy and radiotherapy. We call this combination- (or concurrent) chemoradiotherapy.
- Trial name
- PANORAMIC (NCT01262183)
- Testing
- CRT + Panitumumab, Concurrent chemoradiation therapy without panitumumab
- Where
- Netherlands
- Volunteers
- 4 people
- Sponsor
- Radboud University Medical Center
Advanced Relapsed Tumors, Refractory Solid Tumors
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
This is an open-label Phase 1a/b dose-escalation study to assess the safety, tolerability, and PK of OMP-131R10 as a single agent for advanced solid tumors and in subjects with metastatic colorectal cancer.
- Trial name
- NCT02482441
- Testing
- OMP-131R10, FOLFIRI
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Anal Cancer, Anal Carcinoma
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group
The RADIANCE multicenter, randomized phase II trial will assess the efficacy of durvalumab, a PD-L1 immune checkpoint inhibitor, in combination with primary mitomycin C (MMC)/5-fluorouracil (5-FU)-based radiochemotherapy (RCT) in…
- Conditions
- Anal Cancer, Anal Carcinoma, Anal Cancer Stage III, Anal Cancer Stage II
- Trial name
- RADIANCE (NCT04230759)
- Testing
- Chemotherapy, Radiation, Durvalumab
- Where
- 25 sites in Austria, Germany and 1 more
- Volunteers
- 180 people
- Sponsor
- Goethe University
Nasopharyngeal Carcinoma
Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma
This randomized clinical trial determining whether Sintilimab plus Capecitabine versus Capecitabine alone can improve the progression-free survival rate of NPC patients with unfavorable response to induction chemotherapy.
- Trial name
- NCT05201859
- Testing
- Sintilimab, Capecitabine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-sen University
Vaginal Atrophy
Clinical Study of the CO2RE Laser Device Performance for Vaginal Atrophy Treatments
The CO2RE laser system is a fractional CO2 laser that is FDA approved under a 510(k) K101321 for dermatologic procedures requiring ablation and coagulation of soft tissues, including the skin Eligible subjects will undergo 3…
- Trial name
- NCT02704741
- Testing
- CO2RE
- Where
- 4 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Syneron Medical
Rectal Neoplasms, Adenocarcinoma
Preoperative Chemoradiation Followed by Chemotherapy for Locally Advanced Rectal Cancer
The current standard treatment of locally advanced rectal cancer (clinical stage II or III) is preoperative radiation with chemotherapy (CRT) followed by surgery.
- Trial name
- PREPARE (NCT01952951)
- Testing
- Capecitabine Oxaliplatin, pelvic radiation capecitabine 5-fluorouracil
- Where
- 7 sites in South Korea
- Volunteers
- 110 people
- Sponsor
- National Cancer Center, Korea
Gastric Cancer
Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different combinations and combining them with interferon alfa and G-CSF may kill more tumor…
- Trial name
- NCT00003172
- Testing
- filgrastim, recombinant interferon alfa, docetaxel
- Where
- 25 sites in United States, South Africa
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer
Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
This trial will compare 6 versus 12 months of trastuzumab in combination with dose dense docetaxel following FE75C as adjuvant chemotherapy in women with axillary lymph node positive breast cancer overexpressing HER2
- Trial name
- NCT00615602
- Testing
- Docetaxel, Trastuzumab, Epirubicin
- Where
- 10 sites in Greece
- Volunteers
- 489 people
- Sponsor
- Hellenic Oncology Research Group
Esophageal Cancer
Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma
This is a randomized noninferiority multicenter trial. Patients will be stratified according to the participating hospital. Patients will be randomized to one of the treatment arms.
- Trial name
- ASSURE (NCT03306901)
- Testing
- Esophagectomy, 5-fluorouracil, Cisplatin
- Where
- 9 sites in South Korea
- Volunteers
- 240 people
- Sponsor
- Samsung Medical Center
Head and Neck Cancer
Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer
The purpose of this study is to explore the activity of ZD1839 added to concurrent chemoradiotherapy and as adjuvant monotherapy in patients with locally advanced head and neck cancer.
- Trial name
- NCT01185171
- Testing
- ZD 1839 500mg
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Chicago
Pancreatic Cancer, Metastatic Pancreatic Cancer
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic).
- Conditions
- Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT07409272
- Testing
- Setidegrasib, Oxaliplatin, Leucovorin
- Where
- 104 sites in United States, Brazil and 9 more
- Volunteers
- 614 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Peripheral Neuropathy
Estimate the Efficacy of HD6610 Granule for Oxaliplatin-induced Peripheral Neuropathy
The purpose of this study is to estimate the usefulness and safety of HD6610 granule for oxaliplatin-induced peripheral neuropathy.
- Trial name
- NCT02590367
- Testing
- FOLFOX regimen, HD6610 Granule
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Jiangsu Province Hospital of Traditional Chinese Medicine
Stage I Colon Cancer, Stage II Colon Cancer
Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER
This is a Phase II open-label trial of neoadjuvant immunochemotherapy with Atezolizumab and CAPOX followed by surgery and potentially adjuvant chemotherapy for patients with localized resectable pMMR adenocarcinoma of the colon…
- Conditions
- Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer
- Trial name
- NICER (NCT05870800)
- Testing
- Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2, Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2, Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Baylor College of Medicine
Rectal Cancer Recurrent
Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer
JCOG1801 is a randomized phase III trial which was initiated in Japan in August 2019 to confirm the superiority of preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for local relapse-free survival over…
- Trial name
- JCOG1801 (NCT04288999)
- Testing
- Chemotherapy, Preoperative radiotherapy, Procedure
- Where
- 45 sites in Japan
- Volunteers
- 110 people
- Sponsor
- National Cancer Center Hospital East
Colon Cancer
FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer
This project consists of two independent, following specific eligibility criteria and different randomisation schemes studies, later on called DURATION study and BEV study.
- Trial name
- TOSCA (NCT00646607)
- Testing
- FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)
- Where
- 111 sites in Italy
- Volunteers
- 3,756 people
- Sponsor
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
ctDNA, Chemotherapy
Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer
This study will utilize ctDNA methylation detection to evaluate patients with high-risk T3N0 stage II colorectal cancer who are ctDNA-positive one month after surgery.
- Conditions
- ctDNA, Chemotherapy, Colorectal Cancer
- Trial name
- CLEAR-02 (NCT07562711)
- Testing
- Capecitabine, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.